Phase 1 Anxiety Clinical Trials
33 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 33 trials
Recruiting
Phase 1
ACT for Individuals With MNCD and Their Care Partners
Depression in AdultsAnxiety Disorder GeneralizedGrief
Texas Tech University100 enrolled1 locationNCT07239609
Recruiting
Phase 1Phase 2
Acceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease
Quality of LifeDepression, AnxietyStress Reaction+1 more
Children's Hospital Los Angeles66 enrolled1 locationNCT05685368
Recruiting
Phase 1
Open-Label Psilocybin Study in Transdiagnostic Population
AnxietyDepression - Major Depressive DisorderPTSD+5 more
Yale University50 enrolled1 locationNCT06442423
Not Yet Recruiting
Phase 1
Part C: A Phase 1 trial to assess the effect of food on SPT-320 in Healthy Participants.
Anxiety
Seaport Therapeutics Australia Pty lTD36 enrolled1 locationACTRN12625001137482
Recruiting
Phase 1
Intraoperative Midazolam on Delirium Outcome of Elderly Patients
AnxietyDelirium
Chinese PLA General Hospital612 enrolled1 locationNCT06963112
Recruiting
Phase 1
Use of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use
Depression, AnxietyAnxietyDepression - Major Depressive Disorder+1 more
Trustees of Dartmouth College15 enrolled1 locationNCT06920238
Not Yet Recruiting
Phase 1
Testing the Safety and Effects of the Psychedelic Psilocin on Wellbeing and Anxiety in People with Ongoing Physical and Mental Health Conditions
Chronic Fatigue SyndromeAnorexia NervosaFibromyalgia+6 more
Tryptamine Therapeutics66 enrolled1 locationACTRN12625000949482
Recruiting
Phase 1
Part B & Part D: Phase I Single and Multiple-Ascending Dose Trial of SPT-320 in Healthy Participants
Anxiety
Seaport Therapeutics Australia Pty Ltd139 enrolled1 locationACTRN12625000685415
Recruiting
Phase 1
Part A Phase I, Single Ascending Dose Trial of Agomelatine in Healthy Participants
Anxiety
Seaport Therapeutics Australia Pty LTD15 enrolled1 locationACTRN12625000575437
Recruiting
Phase 1Phase 2
Roxadustat for Bone and Neuropsychiatric Aspects in Hemodialysis Patients
Depression Anxiety DisorderKidney Failure, ChronicAnemia in End Stage Renal Disease
Mansoura University46 enrolled1 locationNCT06917950
Recruiting
Phase 1
The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety
AnxietyMedication-refractory Focal-onset Epilepsy
Ohio State University10 enrolled1 locationNCT05032105
Recruiting
Phase 1
Affect of Duavive on Mood & Anxiety Symptoms
MenopauseDepression, AnxietySleep+1 more
St. Joseph's Healthcare Hamilton30 enrolled1 locationNCT04478305
Recruiting
Phase 1Phase 2
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL)
Depression, AnxietyDistress, Emotional
Ottawa Hospital Research Institute20 enrolled2 locationsNCT04754061
Not Yet Recruiting
Phase 1
Efficacy and Safety of Low-dose Cannabidiol for anxiety
Anxiety
PharmaCann Pty Ltd80 enrolled1 locationACTRN12623000803695
Not Yet Recruiting
Phase 1
Cannabidiol (MC-1020) Oro-buccal Spray Administration Clinical Trial
Anxiety
Medlab Clinical10 enrolled1 locationACTRN12622001034729
Withdrawn
Phase 1
Comparative bioavailability assessment between 1 x 60 mg R-192 tablet and 1 x 60 mg R-107 tablet administered orally in healthy participants under fasting conditions.
DepressionAnxiety
Zenith Technology Corporation Limited14 enrolled1 locationACTRN12622000446763
Completed
Phase 1
A study of RLS103 (CBD-Technosphere® Inhalation Powder) in Healthy Adult Volunteers
Social Anxiety DisorderPanic Disorder
Receptor Life Sciences Australia Pty Ltd30 enrolled1 locationACTRN12621001365853
Not Yet Recruiting
Phase 1
A Phase I Trial on The Bioavailability and Half-Life of Sublingually Administered Cannabis Products in Healthy People
Anxiety
Soma Group Limited20 enrolled1 locationACTRN12621000868886
Completed
Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GRX-917 in Healthy Subjects
Anxiety
Gaba Therapeutics Australia Pty Ltd a subsidiary of Gaba Therapeutics, Inc76 enrolled1 locationACTRN12621000160831
Completed
Phase 1
A Multiple Dose Study Evaluating the Pharmacokinetics of an Oral Tablet Formulation of BNC210 in Healthy Volunteers
Anxiety Disorders
Bionomics Limited20 enrolled1 locationACTRN12621000125820